We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Less-Sensitive COVID-19 Tests Could Still Achieve Optimal Results If Enough People Are Tested

By LabMedica International staff writers
Posted on 27 Jul 2021
A computational analysis of COVID-19 tests suggests that, in order to minimize the number of infections in a population, the amount of testing matters more than the sensitivity of the tests that are used.

Researchers from Ashoka University (Haryana, India) and the National Centre for Biological Sciences TIFR (Bangalore, India) used computational models to conduct simulations of how COVID-19 spreads among a population, given different combinations of tests and the economic tradeoffs between them. Accounting for the movement of people between different locations, they calculated the total number of infections that would occur by the end of a pandemic under each scenario.

Different states in India use different mixes of two main tests for COVID-19: a very sensitive reverse-transcriptase polymerase-chain-reaction (RT-PCR) test and a less sensitive rapid antigen test. Traditional thinking holds that an all-RT-PCR approach will ultimately lead to fewer overall infections. While RT-PCR tests are more sensitive than rapid antigen tests, they are more expensive and do not provide results immediately. Therefore, the precise mix of tests needed to optimize outcomes while accounting for cost constraints has been unclear.

Their analysis suggests that using only rapid antigen tests could achieve similar outcomes, in terms of total infections, as using only RT-PCR tests - as long as the number of people tested is high enough. This suggests that governments in lower and middle-income countries might be able to achieve optimal outcomes by concentrating on ramping up testing using less sensitive tests which provide immediate results, rather than favoring RT-PCR.

The researchers also note that governments should continue to explore different mixes of tests that will yield the biggest reduction in the number of cases. Given that the costs of testing are falling, this mix could also be recalibrated regularly to monitor what makes the most economic sense.

"Tests are continually improving, and the tradeoffs are in favor of rapid testing, even if it is less sensitive," said Gautam Menon of Ashoka University. "Modeling the effects of using different combinations of tests, keeping in mind their relative costs, can suggest specific policy changes that will have a substantial effect on changing the trajectory of the epidemic."

Related Links:
Ashoka University
National Centre for Biological Sciences



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Immunofluorescence Analyzer
MPQuanti
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.